ENDRA Life Sciences Inc. (NDRA)
- Previous Close
0.2472 - Open
0.2818 - Bid --
- Ask --
- Day's Range
0.2456 - 0.2818 - 52 Week Range
0.2210 - 2.7900 - Volume
37,025 - Avg. Volume
175,085 - Market Cap (intraday)
2.807M - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-1.5800 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.00
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
www.endrainc.com21
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: NDRA
Performance Overview: NDRA
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NDRA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NDRA
Valuation Measures
Market Cap
2.80M
Enterprise Value
360.24k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.49
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.04
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-82.05%
Return on Equity (ttm)
-156.42%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-10.06M
Diluted EPS (ttm)
-1.5800
Balance Sheet and Cash Flow
Total Cash (mrq)
2.83M
Total Debt/Equity (mrq)
9.60%
Levered Free Cash Flow (ttm)
-5.86M